Association of ABCG2 polymorphisms with susceptibility to anti-tuberculosis drug-induced hepatotoxicity in the Chinese population

References

• Ben Amar J, Dhahri B, Aouina H, Azzabi S, Baccar MA, El Gharbi L, Bouacha H. 2015. Treatment of tuberculosis. Rev Pneumol Clin. 71(2–3):122–129.
   PubMed Web of Science ®Google Scholar
• Castro AT, Mendes M, Freitas S, Roxo PC. 2015. Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years. Rev Port Pneumol (2006). 21(3):144–150.
   PubMed Web of Science ®Google Scholar
• Chen S, Pan H, Chen Y, Lu L, He X, Chen H, Chen R, Zhan S, Tang S. 2019. Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: a nested case-control study. Sci Rep. 9(1):14311.
   PubMed Web of Science ®Google Scholar
• Danan G, Teschke R. 2015. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 17(1):14.
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 95(26):15665–15670. eng.
   PubMed Web of Science ®Google Scholar
• Fraser DJ, Zumsteg A, Meyer UA. 2003. Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene. J Biol Chem. 278(41):39392–39401.
   PubMed Web of Science ®Google Scholar
• Hasan Z, Shakoor S, Hasan R. 2021. Importance of next-generation diagnostics in control of tuberculosis in LMICs. EBioMedicine. 74:103753.
   PubMed Web of Science ®Google Scholar
• He L, Guo Y, Deng Y, Li C, Zuo C, Peng W. 2017. Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin. Xenobiotica. 47(2):154–163.
   PubMed Web of Science ®Google Scholar
• Heerfordt IM, Lerche CM, Wulf HC. 2020. Trends in erythrocyte protoporphyrin IX concentration by age, sex and season among patients with erythropoietic protoporphyria-20 years of follow-up. Photodiagnosis Photodyn Ther. 32:101928.
   PubMed Web of Science ®Google Scholar
• Jiri M, Zhang L, Lan B, He N, Feng T, Liu K, Jin T, Kang L. 2016. Genetic variation in the ABCG2 gene is associated with gout risk in the Chinese Han population. Clin Rheumatol. 35(1):159–163.
   PubMed Web of Science ®Google Scholar
• Kitajima Y, Ishii T, Kohda T, Ishizuka M, Yamazaki K, Nishimura Y, Tanaka T, Dan S, Nakajima M. 2019. Mechanistic study of PpIX accumulation using the JFCR39 cell panel revealed a role for dynamin 2-mediated exocytosis. Sci Rep. 9(1):8666.
   PubMed Web of Science ®Google Scholar
• Kobuchi H, Moriya K, Ogino T, Fujita H, Inoue K, Shuin T, Yasuda T, Utsumi K, Utsumi T. 2012. Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation. PLoS One. 7(11):e50082.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Schuetz JD. 2011. The role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival. Curr Pharm Biotechnol. 12(4):647–655.
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, Klaassen CD, Gonzalez FJ, Ma X. 2013. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med. 19(4):418–420.
   PubMed Web of Science ®Google Scholar
• Li WD, Jiao H, Wang K, Zhang CK, Glessner JT, Grant SF, Zhao H, Hakonarson H, Arlen Price R. 2013. A genome wide association study of plasma uric acid levels in obese cases and never-overweight controls. Obesity (Silver Spring). 21(9):E490–494.
   PubMed Web of Science ®Google Scholar
• Lin YH, Chang HM, Chang FP, Shen CR, Liu CL, Mao WY, Lin CC, Lee HS, Shen CN. 2013. Protoporphyrin IX accumulation disrupts mitochondrial dynamics and function in ABCG2-deficient hepatocytes. FEBS Lett. 587(19):3202–3209.
   PubMed Web of Science ®Google Scholar
• Mathews DH, Turner DH, Watson RM. 2016. RNA secondary structure prediction. Curr Protocol Nucleic Acid Chem. 67(1):11.12.11–11.12.19.
   Google Scholar
• Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. 2005. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol. 67(5):1765–1771.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Ross DD. 2012. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 31(2):73–99.
   PubMed Web of Science ®Google Scholar
• Prasad B, Lai Y, Lin Y, Unadkat JD. 2013. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J Pharm Sci. 102(3):787–793.
   PubMed Web of Science ®Google Scholar
• Ramappa V, Aithal GP. 2013. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 3(1):37–49.
   PubMedGoogle Scholar
• Sachar M, Anderson KE, Ma X. 2016. Protoporphyrin IX: the good, the bad, and the ugly. J Pharmacol Exp Ther. 356(2):267–275.
   PubMed Web of Science ®Google Scholar
• Sachar M, Li F, Liu K, Wang P, Lu J, Ma X. 2016. Chronic treatment with isoniazid causes protoporphyrin IX accumulation in mouse liver. Chem Res Toxicol. 29(8):1293–1297.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhu M, Shen W, Wang C, Dai J, Xu L, Jin G, Hu Z, Ma H, Shen H. 2017. A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population. Pharmacogenomics J. 17(3):280–285.
   PubMed Web of Science ®Google Scholar
• Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. 2008. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 23(2):192–202.
   PubMed Web of Science ®Google Scholar
• Yang M, Pan H, Lu L, He X, Chen H, Tao B, Liu W, Yi H, Tang S. 2019. Home-based anti-tuberculosis treatment adverse reactions (HATTAR) study: a protocol for a prospective observational study. BMJ Open. 9(3):e027321.
   PubMed Web of Science ®Google Scholar
• Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, Ding Y, Duan ZP, Fu QC, Guo XY, et al. 2017. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 11(3):221–241.
   PubMed Web of Science ®Google Scholar
• Zha BS, Nahid P. 2019. Treatment of Drug-Susceptible Tuberculosis. Clin Chest Med. 40(4):763–774. eng.
   PubMed Web of Science ®Google Scholar
• Zhang T, Du J, Yin X, Xue F, Liu Y, Li R, Luo C, Li L, Li X. 2015. Adverse events in treating smear-positive tuberculosis patients in China. Int J Environ Res Public Health. 13(1):86.
   Web of Science ®Google Scholar
• Zhao H, Wang Y, Zhang T, Wang Q, Xie W. 2020. Drug-induced liver injury from anti-tuberculosis treatment: a retrospective cohort study. Med Sci Monit. 26:e920350.
   PubMed Web of Science ®Google Scholar
• Zhong T, Fan Y, Dong XL, Guo X, Wong KH, Wong WT, He D, Liu S. 2021. An investigation of the risk factors associated with anti-tuberculosis drug-induced liver injury or abnormal liver functioning in 757 patients with pulmonary tuberculosis. Front Pharmacol. 12:708522.
   PubMed Web of Science ®Google Scholar